Bring the benefit of Stelo to your patients
Start patients on their glucose health journey and expand the offerings in your practice with a wholesale purchase of Stelo, the personal glucose biosensor
Bulk up your clinic's offerings
Resell Stelo and offer patients powerful glucose sensing technology
- Wholesale pricing: Discounted rates on bulk orders of Stelo Glucose Biosensors
- Available for minimum order: 48 count of 2-pack (up to 30-day supply)
- No contracts or commitment: Buy as needed with no obligation to repurchase on a fixed schedule
- Access to reseller toolkit: Digital and print ready materials will be provided to support the promotion of Stelo
Want to get more information or ready to put your order in?
If your clinic bills insurance, it’s important to understand the Current Procedural Terminology (CPT) codes associated with glucose sensing. Click below to learn more about CPT codes and frequently asked questions regarding billing guidelines for Medicare and private insurance patients.
Personalized insights. Personal success.
Individualized feedback drives better understanding of glucose health, empowering patients to achieve their glucose goals*,1-4
Stelo Glucose Biosensor is for patients ages 18 years and older with1:
- Type 2 diabetes not on insulin
- Prediabetes
- An interest in tracking their glucose for health insights
And for patients who want to:
- Spend more time in their target glucose range and lower A1C for better control of type 2 diabetes*5,7
- Stay healthy or improve their health by better understanding how lifestyle and behavior modifications impact glucose*,1-4
- Get the most out of their GLP-1 agonist†,6
*Results obtained from previous Dexcom device(s) in patients with diabetes. †Both single and dual agonists.
1 Stelo User Guide. 2 Ehrhardt N, et al. Clin Diab. 2020;38(2):1-6. 3 Porter M, et al. J Diabetes Sci Technol. 2022;16(2):578-580. 4 Clark T, et al. Diabetes Technol Ther. 2024. 26(9). 5 Layne JE, et al. Diabetes Technol Ther. 2024;26(12):925-31. 6 Nemlekar et al. Diabetes Technol Ther. 2024;26(Supp 2):A206-7. 7 2 Reed J, et al. Diabetes Obes Metab. 2024;26(7):2881-9.
MAT-12908